Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: Valganciclovir Strategies and Everolimus in Heart Transplant
NCT00966836Phase 3Unknown
- Sponsor
- Alma Mater Studiorum – Università di Bologna
- Start
- Apr 2009
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valganciclovir, everolimus in cardiac allograft vasculopathy (CAV), cytomegalovirus infection (CMV), sponsored by Alma Mater Studiorum – Università di Bologna. Status: unknown.
02
Drugs
valganciclovireverolimus
03
Conditions
cardiac allograft vasculopathy (CAV)cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00966836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00966836.